Showing 1 – 20 of 1369
Relevance | Newest | Oldest |
  • JAMA March 1, 2016

    Figure 2: Efficacy of Treatment to Prevent Acute Kidney Injury (AKI) in All Patients and Prespecified Subgroups

    Absolute differences are the estimated differences in proportions between the atorvastatin and placebo groups derived from model transformations. Quasi-Poisson log-linear regression was used to calculate the estimates and 95% CIs. The estimates should be interpreted as the relative risk of treatment for the primary end point of AKI. The Pearson χ2 test was used to calculate the P values.
  • JAMA December 3, 2014

    Figure 1: Assessment, Randomization, and Follow-up of Study Patients

    AKI indicates acute kidney injury; ICU, intensive care unit; RRT, renal replacement therapy (dialysis).
  • JAMA October 17, 2012

    Figure 1: Development of Stage 2 or 3 Acute Kidney Injury (AKI) While in the Intensive Care Unit (ICU)

    Stage 2 or 3 defined according to the Kidney Disease: Improving Global Outcomes clinical practice guideline.
  • JAMA May 24, 2016

    Figure 1: Flow of Patients Through the ELAIN Trial

    ELAIN indicates Early vs Late Initiation of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury; KDIGO, Kidney Disease: Improving Global Outcomes; RRT, renal replacement therapy; CKD, chronic kidney disease; GFR, glomerular filtration rate; AKI, acute kidney injury; SOFA, sepsis-related organ failure assessment; NGAL, neutrophil gelatinase–associated lipocalin.
  • JAMA September 16, 2009

    Figure 3: Risk of Chronic Dialysis Associated With Acute Kidney Injury and Dialysis at Index Hospitalization by Participant Characteristics

    aThe numerator denotes the number of events (requirement for chronic dialysis) and the denominator denotes the number of patients at risk within that subgroup. Hazard ratios are adjusted for the propensity score for acute kidney injury and dialysis and participant age. Effect estimates are not shown; models did not converge.
  • JAMA June 14, 2016

    Figure: Flowchart of Enrolled Participants and Progress Through the LIPS-A Trial

    Reasons for exclusion were not mutually exclusive and exhaustive because participants could have more than 1 reason for exclusion. Exclusion after randomization (n = 10) resulted in a change from an intention-to-treat analysis to a modified intention-to-treat analysis denoted as the full analysis set in International Conference on Harmonization statistical guidelines (E9 guidelines). The full analysis set was used for all analyses. The ineligibility reasons for the 4 participants withdrawn from the intention-to-treat sample were allergy to aspirin confirmed before first dose but after randomization; non-English speaking and removed per institutional review board determination; participant enrolled into study twice (second enrollment excluded); and patient was determined to have acute kidney injury after consent but prior to first dose. The 6 participants who withdrew consent indicated that previously collected data could not be used in the study.
  • JAMA March 1, 2016

    Figure 1: Recruitment, Randomization, and Follow-up for the Statin Acute Kidney Injury Cardiac Surgery RCT

    RCT indicates randomized clinical trial.aThese are approximate data.
  • JAMA February 8, 2006

    Figure: Critically Ill Patients and Acute Renal Failure

  • JAMA February 8, 2006

    Figure: Critically Ill Patients and Acute Renal Failure

  • Acute Renal Failure

    Abstract Full Text
    JAMA. 2002; 288(20):2634-2634. doi: 10.1001/jama.288.20.2634
  • From JAMA ’s Daily News Site

    Abstract Full Text
    JAMA. 2013; 310(20):2138-2138. doi: 10.1001/jama.2013.283176
  • JAMA December 3, 2014

    Figure 2: Perioperative Aspirin and the Risk of Acute Kidney Injury in Subgroups

    The size of the markers reflects the size of the sample.aAdjusted for 15 covariates plus preoperative chronic kidney disease, clonidine allocation therapy, and the long-term use of aspirin prior to randomization when appropriate (see Methods).bChronic kidney disease was defined as a preoperative estimated glomerular filtration rate of 60 mL/min per 1.73 m2 or less. The relative risk (RR) of acute kidney injury with aspirin vs placebo did not significantly differ in those with vs without preoperative chronic kidney disease (P = .53 for interaction).cThe RR of acute kidney injury with aspirin vs placebo did not significantly differ in those who were vs were not taking long-term aspirin prior to randomization (P = .45 for interaction).
  • JAMA December 3, 2014

    Figure 3: Perioperative Clonidine and the Risk of Acute Kidney Injury in Subgroups

    The size of the markers reflects the size of the sample.aAdjusted for 16 covariates (17 covariates minus preoperative chronic kidney disease) and adjusted for aspirin allocation therapy (see Methods).bChronic kidney disease was defined as a preoperative estimated glomerular filtration rate of 60 mL/min per 1.73 m2 or less. The relative risk (RR) of acute kidney injury with clonidine vs placebo did not significantly differ in those with vs without preoperative chronic kidney disease (P = .57 for interaction).
  • JAMA April 12, 2016

    Figure 3: Genome-Wide Transcriptional Analysis of Blood Leukocytes From Patients With Sepsis Who Did or Did Not Acquire an Infection While in the ICU

    A, Genome-wide blood gene expression profiles of 64 patients who developed an intensive care unit (ICU)–acquired infection and 398 patients who did not were each compared to 42 healthy controls. This analysis revealed 97% of the significantly altered gene transcripts in patients with and without acquired infection were common. Log2 fold changes relate to differences in gene expression between patients and healthy controls. Spearman correlation analysis of the resultant log2-transformed fold changes of standard biotin-fluorescence intensities per gene transcript between patients and healthy subjects (intensity genei,patients − intensity genei,health) showed a strongly correlating gene expression response. No differences in blood transcriptional profiles were uncovered when directly comparing patients with and without ICU-acquired infections with samples from patients with no ICU-acquired infection. ρ Indicates Spearman ρ. Each dot represents a specific gene transcript. B and C, Volcano plot representation (integrating log2 fold changes and −log10 Benjamin Hochberg [BH] P values) of genome-wide blood transcriptional profiles of paired ICU admission and event (follow-up) samples from 9 patients with no and 19 patients with ICU-acquired infections. Log2 fold changes relate to the difference in gene expression between (paired) admission and follow-up samples. Each dot represents a specific gene transcript. B, Gene expression profiles of patients without ICU-acquired infections sampled at ICU admission were compared with those sampled at the onset of a noninfectious ICU-acquired complication (2 acute lung injuries, 6 acute kidney injuries; 1 acute myocardial infarction). No differences were identified. C, Gene expression profiles of patients with ICU-acquired infections sampled at ICU admission were compared with samples taken at the onset of an ICU-acquired infectious complication. A total of 128 significantly different genes were identified in the paired samples of patients with ICU-acquired infections. Gray dots denote nonsignificant genes; red dots, significantly overexpressed genes (n=11); blue dots, significantly underexpressed genes (n=117). D, Heat map representation of samples from 19 patients with ICU-acquired infections collected at both ICU admission and at the onset of the infectious complication (paired analysis). Glycolysis-I gene expression values (log2-transformed intensities) were scaled and depicted in color code format, with red denoting overexpression and blue denoting underexpression. GPI indicates glucose-6-phosphate isomerase; TPI1, triosephosphate isomerase 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PGK1, phosphoglycerate kinase 1; PGAM1, phosphoglycerate mutase 1; and ENO1, enolase 1.
  • JAMA December 18, 2013

    Figure 2: Chronic Kidney Disease, Statin Use, and the Risk of Acute Kidney Injury From Coprescription

    The outcome was 30-day hospitalization with acute kidney injury assessed by diagnostic codes. The referent group was patients with evidence of azithromycin coprescription. Data marker size is proportional to the inverse of the source variance. CKD indicates chronic kidney disease; NNH, number needed to harm; and OR, odds ratio.